Helix BioPharma Corp., a clinical-stage oncology company, announced immediate changes to its Board of Directors on August 14, 2026. Janusz Grabski has resigned from the board, and Thomas Mehrling, M.D., Ph.D., who serves as Helix's Chief Executive Officer, has been formally appointed as a director. This appointment follows the board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
The board changes are intended to ensure that Helix's board continues to meet the company's evolving governance and capital markets requirements. The statement from the company emphasizes that the new composition brings the experience needed to support Helix's clinical development and broader corporate objectives. Helix expressed gratitude to Mr. Grabski for his service and contributions.
This governance shift comes at a pivotal time for Helix, which is advancing a pipeline focused on difficult-to-treat cancers. The lead candidate, L-DOS47, is an antibody-enzyme conjugate in clinical development as a combination therapy for non-small cell lung cancer (NSCLC). Additionally, the company is developing LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors.
The appointment of Dr. Mehrling to the board is significant because it aligns leadership with governance, potentially streamlining decision-making and reinforcing the strategic direction set by management. As CEO, Dr. Mehrling has been instrumental in guiding Helix's clinical programs and corporate strategy. His presence on the board could facilitate more direct communication between the board and executive team, which is often beneficial for a clinical-stage company navigating complex regulatory and financial landscapes.
For investors and stakeholders, this change signals a commitment to maintaining strong governance practices while focusing on advancing the company's pipeline. The inclusion of the CEO on the board is a common practice in the biotech industry, especially when the CEO has deep scientific expertise, as Dr. Mehrling does with his M.D. and Ph.D.
Helix BioPharma's shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0). The company continues to focus on addressing unmet medical needs in oncology, and these board changes are part of its broader efforts to position itself for future growth.
For more information about Helix BioPharma and its pipeline, interested parties can visit the company's website at https://www.helixbiopharma.com/. Additional details about the acquisition from Laevoroc Group can be found at this link.
